[61] demonstrated that the CRISPR/Cas9 procedure could particularly goal and cleave conserved regions within the HBV genome, resulting in strong suppression of viral gene expression and replication both in vitro and in vivoWe also demonstrated that AZD4547, administered for ten months over the risk window for mammary tumor improvement in MMTV-ErbB2